Home > > > Pancreatic Cancer Market Poised for Growth as Precision Medicine and Immunotherapy Advance

Pancreatic Cancer Market Poised for Growth as Precision Medicine and Immunotherapy Advance

Author : John snow | Published On : 16 Oct 2026

Pancreatic Cancer Market Overview

The pancreatic cancer market is expected to expand across the seven major markets (7MM), comprising the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, through 2034. Growing investment in clinical research, advances in diagnostic technologies, and the development of targeted therapies and immunotherapies are expected to influence the treatment landscape. According to DelveInsight, the market outlook reflects increasing efforts to address unmet medical needs through innovative treatment approaches and a growing pipeline of investigational candidates.

DelveInsight's Pancreatic Cancer Market Insights report provides an in-depth assessment of current treatment practices, emerging therapies, competitive dynamics, epidemiological trends, and historical and forecasted market sizes from 2020 to 2034.

Explore the Pancreatic Cancer Market Insights for comprehensive market forecasts and competitive analysis - https://www.delveinsight.com/report-store/pancreatic-cancer-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Pancreatic Cancer Market Summary

The pancreatic cancer treatment market is projected to experience substantial growth as pharmaceutical companies advance novel therapies. The United States represented the largest share of the 7MM market in 2024, supported by its substantial patient population and evolving treatment landscape. DelveInsight estimates that approximately 63,000 new pancreatic cancer cases were reported in the United States in 2024.

Several pharmaceutical and biotechnology companies are developing treatments intended to improve clinical outcomes. Key participants include Lokon Pharma, Revolution Medicines, Oncotelic, Novocure, BioNTech, Genentech, Elicio Therapeutics, Jiangsu Hengrui Pharmaceuticals, Tyligand Pharmaceuticals (Suzhou), and Jacobio Pharmaceuticals.

Promising investigational candidates include LOAd703, daraxonrasib, BNT122, OT-101, ELI-002, Optune, HRS-4642, TSN1611, and glecirasib. Their clinical progress could influence future treatment strategies and competitive positioning.

Discover the pancreatic cancer new treatment @ https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Key Factors Driving the Pancreatic Cancer Market

Rising Pancreatic Cancer Incidence

An aging population and the prevalence of risk factors, including smoking, obesity, diabetes, and chronic pancreatitis, contribute to the pancreatic cancer burden. Increasing patient numbers create a greater need for early diagnosis, effective treatment, and improved disease management. However, symptoms frequently appear at advanced stages, making timely detection challenging.

Advancements in Immunotherapy

Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, is often characterized as an immunologically cold tumor. Its complex tumor microenvironment can limit immune responses, creating challenges for immunotherapy. Researchers are evaluating immune checkpoint inhibitors targeting PD-1 and PD-L1 alongside chemotherapy, radiation, and targeted agents to improve therapeutic effectiveness.

Precision Medicine and Targeted Therapies

Precision medicine is becoming increasingly important as researchers identify molecular alterations associated with pancreatic cancer. KRAS, BRCA, and NRG1 are among the targets attracting significant research interest. Targeted therapies designed for specific genetic alterations may help identify patient populations more likely to benefit from treatment.

Combination strategies are also being investigated to overcome resistance mechanisms, improve response rates, and extend disease control.

Pancreatic Cancer Treatment Landscape and Market Analysis

Treatment decisions depend on disease stage, tumor characteristics, molecular findings, and patient eligibility. Standard approaches include surgery, chemotherapy, and radiation, while targeted therapies and immunotherapies are expanding options for selected patient groups.

Approved treatments include LYNPARZA (olaparib; AstraZeneca), VITRAKVI (larotrectinib; Bayer), ROZLYTREK (entrectinib; Genentech), KEYTRUDA (pembrolizumab; Merck), and BIZENGRI (zenocutuzumab; Merus and Partner Therapeutics). Their use depends on relevant clinical and molecular indications.

The treatment landscape remains heavily influenced by first-line systemic therapies, although research into neoadjuvant and adjuvant approaches continues. HOIST is also investigating HM-001 for carcinomatous peritonitis and peritoneal dissemination, alongside an ALKBH3 inhibitor. Preclinical findings have indicated activity in pancreatic cancer patient-derived xenograft models, warranting further investigation.

To know more about pancreatic cancer treatment options, visit @ https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Pancreatic Cancer Competitive Landscape and Emerging Therapies

The pancreatic cancer pipeline includes multiple candidates designed to address different disease stages and molecular subtypes.

Revolution Medicines' daraxonrasib is an oral, multi-selective RAS(ON) inhibitor designed to target active RAS proteins, including oncogenic variants. The investigational therapy is being evaluated in clinical trials for metastatic PDAC, including the Phase III RASolute-302 study in previously treated patients. Its development highlights growing interest in targeting RAS signaling, a major driver of pancreatic cancer.

BNT122, developed by BioNTech and Genentech, is an individualized mRNA-based cancer vaccine intended to generate immune responses against tumor-specific neoantigens. A Phase II study is evaluating the approach in resected PDAC alongside atezolizumab and subsequent modified FOLFIRINOX chemotherapy.

Optune, developed by Novocure, uses Tumor Treating Fields (TTFields), which deliver alternating electric fields intended to disrupt cancer cell division. The technology is being investigated alongside chemotherapy for locally advanced pancreatic cancer.

OT-101 (trabedersen), developed by Oncotelic, is an antisense oligonucleotide targeting transforming growth factor-beta 2 (TGF-β2) mRNA. It is being studied in combination with modified FOLFIRINOX for advanced, unresectable, or metastatic pancreatic cancer.

Additional investigational candidates include ELI-002 from Elicio Therapeutics, HRS-4642 from Jiangsu Hengrui Pharmaceuticals, TSN1611 from Tyligand Pharmaceuticals (Suzhou), and glecirasib from Jacobio Pharmaceuticals. These programs explore different therapeutic strategies, including immune activation and KRAS-directed treatment.

Discover more about therapy for pancreatic cancer @ https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Recent Developments in the Pancreatic Cancer Market

Several developments reported in 2025 highlighted continued innovation in pancreatic cancer treatment:

  • In September 2025, Revolution Medicines announced clinical updates concerning daraxonrasib and the initiation of RASolute-303, a Phase III study evaluating the candidate as a first-line treatment for metastatic PDAC.

  • In August 2025, Novocure submitted a Premarket Approval application to the US FDA for TTFields therapy in locally advanced pancreatic cancer, supported by findings from the Phase III PANOVA-3 trial.

  • In June 2025, the US FDA granted Breakthrough Therapy Designation to daraxonrasib for previously treated metastatic PDAC involving KRAS G12 mutations.

  • In May 2025, Novocure presented Phase III PANOVA-3 results evaluating TTFields with gemcitabine and nab-paclitaxel at the American Society of Clinical Oncology meeting.

  • In March 2025, PEP-010 received Orphan Drug Designation from the US FDA for its potential use in metastatic pancreatic cancer.

These milestones demonstrate the continued emphasis on targeted therapies, combination regimens, and innovative treatment technologies. Regulatory outcomes and subsequent clinical evidence will determine their eventual clinical and commercial impact.

Pancreatic Cancer Epidemiology

Pancreatic cancer develops in the tissues of the pancreas, an organ involved in digestion and blood glucose regulation. PDAC accounts for the majority of pancreatic malignancies and is associated with an aggressive disease course. Common symptoms include abdominal pain, jaundice, unexplained weight loss, and fatigue, although these may not become apparent until the disease has advanced.

DelveInsight estimates that exocrine pancreatic cancers account for more than 90% of pancreatic cancer cases. The report examines historical and forecasted epidemiological trends across the 7MM from 2020 to 2034.

Key segments include total incident cases, stage-specific cases, cancer-type-specific cases, age-specific cases, molecular alteration-specific cases, and treated patients by line of therapy. These insights support assessments of patient needs, treatment adoption, and potential market opportunities.

Discover the latest Pancreatic Cancer Treatment Developments and emerging therapeutic innovations - https://www.delveinsight.com/report-store/pancreatic-cancer-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Conclusion

The pancreatic cancer market is positioned for continued evolution as precision medicine, targeted therapies, and immunotherapy research address persistent treatment challenges. Candidates such as daraxonrasib, BNT122, OT-101, and ELI-002 illustrate the diversity of approaches under investigation. Rising disease burden, improved molecular profiling, and combination treatment strategies may influence future clinical practice. However, the success of emerging therapies will depend on clinical trial outcomes, safety profiles, regulatory decisions, and accessibility. Continued innovation could broaden treatment options and create new commercial opportunities across the 7MM through 2034, while improving the prospects for patients affected by this aggressive disease.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Abhishek kumar

[email protected]